Feed ACAD
AC

ACADIA Pharmaceuticals

ACAD · NASDAQ

$27.74 +0.40% (+$0.11)
1M -5.81%
Market Cap $4.75B
P/E Ratio 12.48x
Div. Yield -
ROE 32.39%

Bulios Fair Price

$19.87

28.4% downside

Trenutna cena

$27.74

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica ACAD trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
4/9
Valuation
51 /100
Fair
P/E 12.48x
PEG 0.17x
EV/EBITDA 38.23x
Growth
100 /100
Growing
Rev. growth 27.48%
Book val. growth 45.26%
EPS growth N/A
Profitability
76 /100
Strong
Gross margin 91.13%
FCF margin 15.32%
Net margin 33.42%
Quality
92 /100
Excellent
ROIC 19.40%
Asset turnover 0.65x
ROE 32.39%
Debt
100 /100
Low
Debt/Equity 0.06x
Net debt/EBITDA -2.68x
Current ratio 3.39x
Stability
52 /100
Moderate
Beta 0.85x
Profitable years 2
Rev. volatility 14.66%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ACAD
Online

O podjetju

ACADIA Pharmaceuticals Inc. (ACAD) is an American biopharmaceutical company focusing on the development of innovative drugs for the treatment of central nervous system disorders. Their main product, pimavanserin, is an approved medication for the treatment of hallucinations and delusions associated with Parkinson's disease. ACADIA Pharmaceuticals actively engages in clinical trials and research to discover new therapeutic options for patients suffering from neurological disorders. ACADIA Pharmaceuticals Inc. (ACAD) shares could be suitable for investors looking to invest in the biopharmaceutical sector with a focus on innovative treatment approaches for neurological conditions.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Catherine E. Owen Adams

Employees

797

Headquarters

San Diego

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

54d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.